Expression of Myeloid Antigen in Neoplastic Plasma Cells Is Related to Adverse Prognosis in Patients with Multiple Myeloma
Figure 3
Kaplan-Meier analysis of (a) PFS and (b) OS in groups of patients with CD13−/CD33−, CD13−/CD33+, CD13+/CD33−, and CD13+/CD33+. The CD13+/CD33+ group showed significantly shorter PFS and OS than other groups: CD13−/CD33− group ( in PFS and OS), CD13+/CD33− group ( in PFS and in OS), and CD13−/CD33+ group ( in PFS, in OS). CD13+/CD33− group showed significantly shorter PFS and OS than CD13−/CD33− group ( in PFS, in OS).
